Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - MYMETICS CORP | mymx_ex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of
1934
Date of
Report (Date of earliest event reported): April 23, 2018 (April 16,
2018)
Mymetics Corporation
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
000-25132
|
|
25-1741849
|
|
(State of other
jurisdiction of incorporation)
|
|
(Commission File
Number)
|
|
(IRS
Employer Identification No.)
|
|
Route de la
Corniche 4
1066
Epalinges, Switzerland
|
|
NA
|
|
(Address of
principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: +011 41 21 653 45
35
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
[ ]
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item
8.01 Other Events.
The
registrant, Mymetics Corporation (“Mymetics”), entered
into a Research and Option to License Agreement (the
“Research Agreement”) dated April 16, 2018, with
Anergis SA (“Anergis”). Under the terms of the Research
Agreement, a pre-clinical study program will evaluate the
immunogenicity profile of the Anergis’ peptides designed to
treat birch allergy when presented on Mymetics’ proprietary
virosomes, with or without undisclosed TLR ligands or other
adjuvants, and will compare the results to Anergis’ AllerT
product combination. The results of the program are expected in the
first quarter of 2019.
In the
event that the results of the pre-clinical study program are
successful, Anergis has the option to obtain an exclusive worldwide
license of Mymetics’ virosome technology for the development
of allergy vaccines. Should Anergis and Mymetics execute a License
and Collaboration Agreement (LCA), Anergis would make an upfront
payment to Mymetics in an amount that increases as the date of
executing the LCA is delayed, milestone payments based on certain
regulatory clearances and royalties for net sales.
Mymetics has issued
a press release summarizing the terms of the Research Agreement, a
copy of which is attached to this Current Report on Form 8-K as
Exhibit 99.1.
Item
9.01. Financial Statements and
Exhibits
(d)
Exhibits.
99.1 Press Release dated
April 23, 2018
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
|
|
MYMETICS
CORPORATION
|
|
|
|
|
|
|
|
|
Date:
April 23, 2018
|
By:
|
/s/
Ronald
Kempers
|
|
|
|
|
Ronald Kempers |
|
|
|
|
President and Chief Executive Officer |
|
3